The aim of the present study, using fecal metagenomics as a snapshot, was to provide more specific understandings on how the gut microbiome influences the responses of HCC patients to anti-PD-1 immunotherapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.